CCII’s Global Network｜Networks｜Center for Cancer Immunotherapy and Immunobiology

CCII’s Global Network
Cancer is a global disease that affects all humans and developing new therapies for cancer is an equally global endeavor. Immune checkpoint inhibitors were first discovered in Japan, but it was global pharmaceutical companies that brought the first anti-PD1 antibodies to market. Our goal at CCII is to become a hub for collaborations with research institutions and companies in Japan and abroad in order to accelerate the translation of new discoveries into new treatments to be delivered to patients. As a research organization, our goal is to collaborate at a global scale and to work with partners in the US, Europe, Asia, Africa, or Oceania. From the outset, we have been building a network with the main research organization in the field of cancer immunotherapy.

Bloomberg-Kimmel Institute for Cancer Immunotherapy　

The Bloomberg-Kimmel Institute for Cancer Immunotherapy is a research center under the Sidney Kimmel Comprehensive Cancer Center at John Hopkins University.
more

University Medical Center Hamburg-Eppendorf (UKE), Department of Tumor Biology

The Department of Tumor Biology at the UKE Hamburg is a leading research organization focused on basic and translational research in liquid biomarkers.
more

Institut Curie

As a leading life sciences and biophysics research organization, the Institut Curie in Paris is also a pioneer in advanced cancer treatment provided at its own hospital.
more

Princess Margaret Cancer Centre

The Princess Margaret Cancer Centre, UHN, is the largest integrated cancer center in Canada.
more

The Moores Cancer Center, San Diego Health

The Moores Cancer Center at San Diego Health is one of the leading cancer centers in the US and a particular focus for CCII and Kyoto University, which has a longstanding relationship with the University of California, San Diego.
more

IFOM

IFOM is a cancer research institute focused on the study of cancer formation and development at molecular level founded by the Italian Cancer Research Foundation FIRC.
more